<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00558246</url>
  </required_header>
  <id_info>
    <org_study_id>07CS003</org_study_id>
    <nct_id>NCT00558246</nct_id>
  </id_info>
  <brief_title>Study of Prineo (Dermabond Protape) Versus Sutures in Breast Procedures</brief_title>
  <official_title>Multi-centre Study to Show Equivalence of Prineo (DERMABOND PROTAPE) to Intradermal Sutures for Skin Closure of Full-thickness Surgical Incisions Associated With Breast Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ethicon, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ethicon, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, controlled, randomized, multi-center clinical study of up to 80
      patients with full thickness surgical incisions associated with bi-lateral breast procedures.
      Breast procedures where symmetrical incisions of at least 15cm in length are planned for both
      breast (bilateral procedure) will be randomised to receive final skin closure of one breast
      with Prineo (DERMABOND PROTAPE) and the other with intradermal sutures (control). Patients
      will be evaluated post-operatively at 24 hours (± 6 hours), 7 days (± 1 day), 12 - 25 days,
      and 90 days (± 10 days).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Continuous Apposition of the Skin Edges Without Wound Dehiscence or Re-closure as Measured by the Upper Limit of 95% Confidence Interval in Proportion of Successes for Each Groups.</measure>
    <time_frame>12-25 days</time_frame>
    <description>Equivalence was demonstrated if the upper limit of the 95% confidence interval (when subtracting the percentage of DERMABOND PROTAPE successful subjects from the percentage of INTRADERMAL SUTURE successful subjects) did not exceed 12 percent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time (Minutes) Required to Close the Final Skin Layer</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Overall time required to close final skin layer on each breast.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmetic Outcome</measure>
    <time_frame>90 days post-procedure</time_frame>
    <description>Modified Hollander Cosmesis Scale overall outcome score in which a score of 0 corresponds to a good outcome versus a 1-6 to a poor outcome. The proportions of breasts with good outcomes were then compared to those with poor outcomes in each group.
Reference: Hollander JE, Singer AJ, Valentine S, Thode HC Jr, Henry MC. Wound registry:development and validation. Ann Emerg Med. 1995;25:675-85.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmetic Outcome</measure>
    <time_frame>6 months</time_frame>
    <description>Modified Hollander Cosmesis Scale overall outcome score in which a score of 0 corresponds to a good outcome versus a 1-6 to a poor outcome. The proportions of breasts with good outcomes were then compared to those with poor outcomes in each group.
Reference: Hollander JE, Singer AJ, Valentine S, Thode HC Jr, Henry MC. Wound registry:development and validation. Ann Emerg Med. 1995;25:675-85.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmetic Outcome</measure>
    <time_frame>12 months</time_frame>
    <description>Modified Hollander Cosmesis Scale overall outcome score in which a score of 0 corresponds to a good outcome versus a 1-6 to a poor outcome. The proportions of breasts with good outcomes were then compared to those with poor outcomes in each group.
Reference: Hollander JE, Singer AJ, Valentine S, Thode HC Jr, Henry MC. Wound registry:development and validation. Ann Emerg Med. 1995;25:675-85.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Macromastia</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On same patient, one breast is randomized to control and one breast is randomized to experimental arm. Patient is own control.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>On same patient, one breast is randomized to control and one breast is randomized to experimental arm. Patient is own control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dermabond Protape (Prineo)</intervention_name>
    <description>cyanoacrylate and pressure sensitive adhesive mesh - topical skin adhesive</description>
    <arm_group_label>I</arm_group_label>
    <other_name>Prineo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Suture</intervention_name>
    <description>Topical Suturing</description>
    <arm_group_label>II</arm_group_label>
    <other_name>Investigator selected the intradermal suture per standard local practice.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be at least 18 years of age;

          -  Be in good general health in the opinion of the Investigator with no conditions that
             would significantly impact wound healing as determined by medical history and review
             of recent concomitant medications;

          -  Require identical skin closure of full-thickness intersecting surgical incisions with
             a combined length of at least 15cm on each breast as part of elective breast
             procedures, requiring the placement of sutures in the superficial fascia and
             subcutaneous tissue to relieve skin tension prior to final skin closure;

          -  Be willing to follow instructions for incision care as instructed by the investigator,
             and refrain from swimming or soaking in a tub until suture removal occurs (during the
             first 12-25 days) of the study;

          -  Agree to return for all follow-up evaluations specified in this protocol [7 days (± 1
             day), 12 - 25 days, and 90 days (± 10 days)], six (± 1 month) and twelve months (± 1
             month)];

          -  Agree not to schedule any additional elective surgical procedures that involve an
             incision that is randomized for inclusion in this study, until their participation in
             this study is complete; and

          -  Sign the informed consent.

        Exclusion Criteria:

          -  Have peripheral vascular disease;

          -  Have insulin dependent diabetes mellitus;

          -  Be known to have a blood clotting disorder;

          -  Be receiving antibiotic therapy for pre-existing condition or infection;

          -  Be known to be HIV-positive or otherwise immunocompromised;

          -  Have known personal or family history of keloid formation or hypertrophy;

          -  Be currently taking systemic steroids;

          -  Have known or suspected allergy or sensitivity to cyanoacrylate, formaldehyde, tapes
             or adhesives

          -  Have incision type or location known to have an incidence of cyanosis or other healing
             abnormalities; and

          -  Be participating in any current clinical trial of an investigational product or have
             participated in any clinical trial of an investigational product within 30 days of
             enrolment in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen Colquhoun, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pleiad Devices</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dreifaltigkeits-Krankenhaus</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Markus Krankenhaus</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademikliniken</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Essex Hospital</name>
      <address>
        <city>Broomfield</city>
        <state>Essex</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2007</study_first_submitted>
  <study_first_submitted_qc>November 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2007</study_first_posted>
  <results_first_submitted>June 13, 2012</results_first_submitted>
  <results_first_submitted_qc>June 13, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 19, 2012</results_first_posted>
  <last_update_submitted>June 13, 2012</last_update_submitted>
  <last_update_submitted_qc>June 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Lift</keyword>
  <keyword>Breast Reduction</keyword>
  <keyword>Breast Reconstruction</keyword>
  <keyword>Plastic Surgery</keyword>
  <keyword>Skin Closure</keyword>
  <keyword>Wound Healing</keyword>
  <keyword>Dermabond</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the genreal popluation of those undergoing elective, bilateral breast surgery.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Prineo and Suture</title>
          <description>On same patient, one breast is randomized to control (intradermal sutures) and one breast is randomized to experimental arm (DERMABOND PROTAPE). Patient is own control. Protape is supplied as a single use mesh device with sufficient adhesive to saturate mesh. Sutures were not supplied.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prineo and Suture</title>
          <description>On same patient, one breast is randomized to control (intradermal sutures) and one breast is randomized to experimental arm (DERMABOND PROTAPE). Patient is own control. Protape is supplied as a single use mesh device with sufficient adhesive to saturate mesh. Sutures were not supplied.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="79"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Continuous Apposition of the Skin Edges Without Wound Dehiscence or Re-closure as Measured by the Upper Limit of 95% Confidence Interval in Proportion of Successes for Each Groups.</title>
        <description>Equivalence was demonstrated if the upper limit of the 95% confidence interval (when subtracting the percentage of DERMABOND PROTAPE successful subjects from the percentage of INTRADERMAL SUTURE successful subjects) did not exceed 12 percent.</description>
        <time_frame>12-25 days</time_frame>
        <population>The primary analysis is based upon intent to treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Prineo</title>
            <description>On same patient, one breast is randomized to control and one breast is randomized to experimental arm. Patient is own control.</description>
          </group>
          <group group_id="O2">
            <title>Suture</title>
            <description>On same patient, one breast is randomized to control and one breast is randomized to experimental arm. Patient is own control.</description>
          </group>
        </group_list>
        <measure>
          <title>Continuous Apposition of the Skin Edges Without Wound Dehiscence or Re-closure as Measured by the Upper Limit of 95% Confidence Interval in Proportion of Successes for Each Groups.</title>
          <description>Equivalence was demonstrated if the upper limit of the 95% confidence interval (when subtracting the percentage of DERMABOND PROTAPE successful subjects from the percentage of INTRADERMAL SUTURE successful subjects) did not exceed 12 percent.</description>
          <population>The primary analysis is based upon intent to treat population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="-5.9" upper_limit="5.9"/>
                    <measurement group_id="O2" value="76" lower_limit="-5.9" upper_limit="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence is demonstrated if the upper limit of the 95% confidence interval (when subtracting the percentage of DERMABOND PROTAPE successful subjects from the percentage of INTRADERMAL SUTURE successful subjects) does not exceed 12%.</non_inferiority_desc>
            <p_value>1.0000</p_value>
            <method>McNemar</method>
            <param_type>Differences in proportion of successes</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.9</ci_lower_limit>
            <ci_upper_limit>5.9</ci_upper_limit>
            <estimate_desc>The level of significance for statistical testing was 0.05 for this study.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time (Minutes) Required to Close the Final Skin Layer</title>
        <description>Overall time required to close final skin layer on each breast.</description>
        <time_frame>Intraoperative</time_frame>
        <population>The analysis is based upon the Intent to Treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Prineo</title>
            <description>On same patient, one breast is randomized to control and one breast is randomized to experimental arm. Patient is own control.</description>
          </group>
          <group group_id="O2">
            <title>Suture</title>
            <description>On same patient, one breast is randomized to control and one breast is randomized to experimental arm. Patient is own control.</description>
          </group>
        </group_list>
        <measure>
          <title>Time (Minutes) Required to Close the Final Skin Layer</title>
          <description>Overall time required to close final skin layer on each breast.</description>
          <population>The analysis is based upon the Intent to Treat population.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.56" spread="1.34"/>
                    <measurement group_id="O2" value="16.22" spread="6.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cosmetic Outcome</title>
        <description>Modified Hollander Cosmesis Scale overall outcome score in which a score of 0 corresponds to a good outcome versus a 1-6 to a poor outcome. The proportions of breasts with good outcomes were then compared to those with poor outcomes in each group.
Reference: Hollander JE, Singer AJ, Valentine S, Thode HC Jr, Henry MC. Wound registry:development and validation. Ann Emerg Med. 1995;25:675–85.</description>
        <time_frame>90 days post-procedure</time_frame>
        <population>There were 60 participants who consented to and ultimately attended all follow-up visits for evaluation of cosmetic outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Prineo</title>
            <description>On same patient, one breast is randomized to control and one breast is randomized to experimental arm. Patient is own control.</description>
          </group>
          <group group_id="O2">
            <title>Suture</title>
            <description>On same patient, one breast is randomized to control and one breast is randomized to experimental arm. Patient is own control.</description>
          </group>
        </group_list>
        <measure>
          <title>Cosmetic Outcome</title>
          <description>Modified Hollander Cosmesis Scale overall outcome score in which a score of 0 corresponds to a good outcome versus a 1-6 to a poor outcome. The proportions of breasts with good outcomes were then compared to those with poor outcomes in each group.
Reference: Hollander JE, Singer AJ, Valentine S, Thode HC Jr, Henry MC. Wound registry:development and validation. Ann Emerg Med. 1995;25:675–85.</description>
          <population>There were 60 participants who consented to and ultimately attended all follow-up visits for evaluation of cosmetic outcome.</population>
          <units>Incisions with good outcome</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cosmetic Outcome</title>
        <description>Modified Hollander Cosmesis Scale overall outcome score in which a score of 0 corresponds to a good outcome versus a 1-6 to a poor outcome. The proportions of breasts with good outcomes were then compared to those with poor outcomes in each group.
Reference: Hollander JE, Singer AJ, Valentine S, Thode HC Jr, Henry MC. Wound registry:development and validation. Ann Emerg Med. 1995;25:675–85.</description>
        <time_frame>6 months</time_frame>
        <population>There were 60 participants who completed all follow-up visits and cosmetic evaluations.</population>
        <group_list>
          <group group_id="O1">
            <title>Prineo</title>
            <description>On same patient, one breast is randomized to control and one breast is randomized to experimental arm. Patient is own control.</description>
          </group>
          <group group_id="O2">
            <title>Suture</title>
            <description>On same patient, one breast is randomized to control and one breast is randomized to experimental arm. Patient is own control.</description>
          </group>
        </group_list>
        <measure>
          <title>Cosmetic Outcome</title>
          <description>Modified Hollander Cosmesis Scale overall outcome score in which a score of 0 corresponds to a good outcome versus a 1-6 to a poor outcome. The proportions of breasts with good outcomes were then compared to those with poor outcomes in each group.
Reference: Hollander JE, Singer AJ, Valentine S, Thode HC Jr, Henry MC. Wound registry:development and validation. Ann Emerg Med. 1995;25:675–85.</description>
          <population>There were 60 participants who completed all follow-up visits and cosmetic evaluations.</population>
          <units>Incisions with good outcome</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2266</p_value>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cosmetic Outcome</title>
        <description>Modified Hollander Cosmesis Scale overall outcome score in which a score of 0 corresponds to a good outcome versus a 1-6 to a poor outcome. The proportions of breasts with good outcomes were then compared to those with poor outcomes in each group.
Reference: Hollander JE, Singer AJ, Valentine S, Thode HC Jr, Henry MC. Wound registry:development and validation. Ann Emerg Med. 1995;25:675–85.</description>
        <time_frame>12 months</time_frame>
        <population>There were 59 participants who completed all follow-up visits and cosmetic evaluations.</population>
        <group_list>
          <group group_id="O1">
            <title>Prineo</title>
            <description>On same patient, one breast is randomized to control and one breast is randomized to experimental arm. Patient is own control.</description>
          </group>
          <group group_id="O2">
            <title>Suture</title>
            <description>On same patient, one breast is randomized to control and one breast is randomized to experimental arm. Patient is own control.</description>
          </group>
        </group_list>
        <measure>
          <title>Cosmetic Outcome</title>
          <description>Modified Hollander Cosmesis Scale overall outcome score in which a score of 0 corresponds to a good outcome versus a 1-6 to a poor outcome. The proportions of breasts with good outcomes were then compared to those with poor outcomes in each group.
Reference: Hollander JE, Singer AJ, Valentine S, Thode HC Jr, Henry MC. Wound registry:development and validation. Ann Emerg Med. 1995;25:675–85.</description>
          <population>There were 59 participants who completed all follow-up visits and cosmetic evaluations.</population>
          <units>Incisions with good outcome</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5078</p_value>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90+/-10 days following treatment</time_frame>
      <desc>Recorded as reported whether spontaneously volunteered or in response to questioning about well-being at all follow-up visits.</desc>
      <group_list>
        <group group_id="E1">
          <title>Prineo</title>
          <description>On same patient, one breast is randomized to control and one breast is randomized to experimental arm. Patient is own control.</description>
        </group>
        <group group_id="E2">
          <title>Suture</title>
          <description>On same patient, one breast is randomized to control and one breast is randomized to experimental arm. Patient is own control.</description>
        </group>
        <group group_id="E3">
          <title>Procedure</title>
          <description>On same patient, one breast is randomized to control and one breast is randomized to experimental arm. Patient is own control.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>Following treatment, patient experienced postoperative sepsis and was hospitalized. Patient required surgical reintervention and was treated with antibiotics. No action was taken with respect to the study.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Elective Brachioplasty</sub_title>
                <description>Subject underwent planned bilateral brachioplasty for hanging skin. The event required hospitalisation for medical/surgical intervention. In the opinion of the Investigator, the event was classified as not related to sutures or Prineo.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Nausea was assessed as not related to device but to procedure.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="79"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="79"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedure Pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Open Wound</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>Events assessed not related device but to procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blistering</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <description>Itchiness at application site assessed as not related to device but to procedure.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <description>Events assessed as not related to device but to procedure.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations of this study include the fact that the patient served as her own control. Additionally, as in many device studies, because of the obvious difference in the investigated and the control devices, blinding was limited.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Phyllis Britnell</name_or_title>
      <organization>Ethicon</organization>
      <phone>1 908 218-3060</phone>
      <email>pbritnel@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

